Ariad’s Leukemia Drug Probed By U.S. Regulators and 2 Other Hot Stocks to Watch
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): Current price $4.59
The Food and Drug Administration said Friday that the safety of Ariad’s leukemia drug Iclusig is being probed by U.S. regulators due to the growing frequency of reports of serious blood clots and the narrowing of blood vessels in patients. “Health-care professionals should consider for each patient, whether the benefits of Iclusig treatment are likely to exceed the risks of treatment,” the FDA said as it urged doctors and patients to report side effects of the drug. Ariad shares plunged by a record 66 percent on Wednesday after the firm reported the FDA had placed a hold on enrollment of all trials of Iclusig because of safety questions among participants. The drug was OK’d in 2012 for two rare forms of leukemia, and Ariad says it will remain on the market.
AT&T Inc. (NYSE:T): Current price $34.04
Sources in a Business Insider report say that AT&T seems to be closing most if not all of its AdWorks offices and ending its trial of mobile and digital ad sales. The carrier confirmed a modification in strategy and some job eliminations in a statement it gave to Business Insider, which said that many if not most staff connected with AdWorks in New York were laid off this week. Sources previously indicated that there were job cuts executed or planned at AdWorks in Los Angeles and Chicago, reported in September. In May, Adworks offered a program named Blueprint, which purported to offer targeted ad buys spanning a range of media, mobile, TV, and online, but the sources now say that the program may no longer be in existence.
The Gap Inc. (NYSE:GPS): Current price $36.63
Shares are down almost 7.5 percent for Gap on Friday after the retailer reported that a key sales figure slid last month, missing analyst expectations. After the market close on Thursday, the clothing company said that sales at stores open a minimum of one year dropped by 3 percent in September versus a 6 percent rise year-over-year. The performance was also below the 1.6 percent gain forecast by Thomson Reuters analysts.
Don’t Miss: Is Gold Good for the Global Economy?